Search This Blog

Wednesday, April 8, 2020

Britain says aiming to roll-out millions of coronavirus tests in months

Britain said on Wednesday it aimed to roll-out millions of coronavirus tests in months after criticism that it had moved too slowly on the issue, adding that a partnership with private firms would help it hit 100,000 tests a day by the end of April.
England’s Chief Medical Officer conceded on Tuesday that there were lessons to learn from Germany on testing.
Foreign Secretary Dominic Raab, who is deputising for Prime Minister Boris Johnson while he is in hospital with COVID-19, has said Britain is making progress to its daily testing target but there was “more work to do.”
The Department of Health said that a new testing laboratory set-up by AstraZeneca, GSK and Cambridge University would aim to carry out 30,000 tests a day by May, and Thermo Fisher would continue to supply the UK with testing kits and aim to scale up manufacturing.
Government testing adviser John Newton said the 100,000 daily test target was feasible, and that 20,000 National Health Service workers had already been tested.
“Testing capacity now is not what we would like, but it is by no means inconsiderable in terms of what we need,” Newton told lawmakers on Wednesday.

“We do anticipate that the need will increase dramatically, and therefore we want to get as much testing in place as possible.”
The government also said a business consortium had launched plans to develop an antibody test, in order to detect those who have been infected with COVID-19 and therefore had immunity.
Newton said he did not expect such tests to be widely available by the end of April and would not rely on them to contribute to the target, even though some laboratory-based antibody tests were beginning to come on stream.
https://www.reuters.com/article/us-health-coronavirus-britain-testing/britain-says-aiming-to-roll-out-millions-of-coronavirus-tests-in-months-idUSKCN21Q290

GM to supply 30,000 ventilators in $500 million U.S. contract

The United States on Wednesday awarded automaker General Motors Co (GM.N) a contract worth $489.4 million to make ventilators needed to treat severely sick coronavirus patients.
The Department of Health and Human Services contract is the first for ventilator production under the Defense Production Act, invoked by President Donald Trump to get companies to produce essential gear needed to fight the pandemic.
GM will work with ventilator firm Ventec Life Systems to deliver 30,000 ventilators under the contract to the U.S. government by the end of August, with deliveries of the first 6,132 ventilators taking place by June 1.
The company “will fulfill the government contract and (has) the capacity to supply more if needed,” GM spokesman Jim Cain said, adding that the contract also includes “consumables and accessories (hoses, stands, etc.) to support each unit.”

GM Vice President Gerald Johnson told Reuters last month the automaker is spending tens of millions on retooling costs as it produces the ventilators, and that if supplier retooling costs are factored in, total retooling costs were in the hundreds of millions of dollars.
Last week, smaller rival Ford Motor Co (F.N) also said it will produce 50,000 ventilators over the next 100 days at a plant in Michigan in cooperation with General Electric Co’s (GE.N) healthcare unit.
https://www.reuters.com/article/us-health-coronavirus-gm/gm-to-supply-30000-ventilators-in-500-million-u-s-contract-idUSKBN21Q1YA

U.S. coronavirus death projection cut, but official warns of ‘second wave’

An influential university model on the U.S. coronavirus pandemic on Wednesday scaled back its projected death toll by 26% to 60,000 but a federal health official warned of a second wave of infections if Americans relax “social distancing” practices.
The downward revision in the death toll in the University of Washington model – often cited by U.S. and state policymakers – coincides with comments by some political leaders that caseloads may have reached a plateau in certain areas.
Those assessments in recent days, including an apparent leveling out in hospitalizations in New York state – the U.S. epicenter of the pandemic – are tempered by a persistent climb in the U.S. death toll, which rose by more than 1,900 on Tuesday as some 30,000 new infections were reported.
New York Mayor Bill De Blasio told a briefing on Wednesday that coronavirus-related hospitalizations in the most populous U.S. city had stabilized and that the need for ventilators was lower than projected.
“In the last few days we’ve actually seen fewer ventilators needed that were projected,” the mayor said.
Even that revised forecast suggested months of pain ahead for the United States. All told, about 400,000 U.S. infections have been reported, along with roughly 13,000 deaths.
“What’s really important is that people don’t turn these early signs of hope into releasing from the 30 days to stop the spread – it’s really critical,” said Deborah Birx, the coordinator of the White House coronavirus task force, referring to guidelines aimed at reducing the spread of the virus.
“If people start going out again and socially interacting, we could see a really acute second wave,” Birx added.
The pandemic has upended American life, with 94% of the population ordered to stay at home and nearly 10 million people losing their jobs in the past two weeks.
Hospitals have been inundated with cases of COVID-19, the respiratory disease caused by the virus, resulting in shortages of medical equipment and protective garments.
The University of Washington’s Institute for Health Metrics and Evaluation model is one of several that the White House task force has cited. It now projects U.S. deaths at more than 60,000 by Aug. 4, down from the nearly 82,000 fatalities it had forecast on Tuesday.
The White House coronavirus task force has previously projected 100,000 to 240,000 Americans could die.
The institute also moved up its projected peak in the number to U.S. deaths to this Sunday, when it predicted 2,212 people will succumb to the disease. The revision moves forward the projected peak by four days, suggesting the strain on the country’s healthcare system will begin to abate a little sooner than previously expected.

AT-HOME DEATHS UNTRACKED
New York’s de Blasio estimated an undercount in the death toll of 100 to 200 people per day who are dying at home but excluded from the city’s rapidly growing coronavirus count. So far the city’s announced death toll has reflected only COVID-19 diagnoses confirmed in a laboratory.
But after a spike in the number of people dying at home, the city will now try to quantify how many of those died from coronavirus-related causes and add that to the its official death toll, New York’s health department said.
“Every single measure of this pandemic is an undercount. Every. Single. One,” Mark Levine, chairman of the City Council’s health committee, wrote on Twitter. “Confirmed cases? Skewed by lack of testing. Hospitalizations? Skewed by huge # of sick people we are sending home because there’s no room in ERs. Deaths? Massive undercount because of dying at home.”
The state of New York accounts for more than a third of U.S. confirmed coronavirus cases, and nearly half the cumulative death toll.
Authorities in various states in recent days have disclosed data showing that the pandemic was having a disproportionate impact on African Americans, reflecting longstanding racial inequities in health outcomes in the United States.
De Blasio said there were “clear inequalities” in how the coronavirus is affecting his city’s population.
In New York, long weeks of fighting the pandemic were taking a toll on hospital staff, some of whom are coming down with the disease they have been fighting.
One resident doctor at New York-Presbyterian Hospital said he had been surprised by the number of hospital workers infected.
“There are people around the hospital who are sick and now they’re showing up on our patient list. … It’s hard not to see yourself in them,” the resident said. “A lot of us feel like we are being put in harm’s way.”
https://www.reuters.com/article/us-health-coronavirus-usa/u-s-coronavirus-death-projection-lowered-new-york-fears-undercount-idUSKBN21Q204

U.S. planning ways to ‘ease’ back to normal if virus efforts work: Fauci

U.S. health officials are planning ways for the country to return to normal activities if distancing and other steps to mitigate COVID-19 this month prove successful in curbing the outbreak, the top U.S. infectious disease official said on Wednesday.
The Trump administration has called for 30 days of measures, including staying at least six feet away from other people, that have upended American life as most people stay isolated at home, shuttering schools and closing businesses through at least the end of April, with some states continuing certain closures through May and June.
Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said such steps must continue but that there are hopeful signs they are working.
“If in fact we are successful, it makes sense to at least plan what a re-entry into normality would look like. That doesn’t mean we’re going to do it right now, but it means we need to be prepared to ease into that,” Fauci, a member of the White House coronavirus task force, told Fox News in an interview.
Fauci and other public health experts have said the strict measures are needed to control the fast-spreading and potentially fatal disease that has already led to about 400,000 confirmed COVID-19 U.S. cases and nearly 13,000 deaths, even as the shutdowns have roiled the U.S. economy.
Dr. Deborah Birx, another task force member, said isolation measures must continue for now or else the country could risk a repeated spike despite the allure of warmer spring weather.

“What’s really important is that people don’t turn these early signs of hope into releasing from the 30 days to stop the spread. It’s really critical,” she told NBC News’ “Today” program. “If people start going out again and socially interacting, we could see a really acute second wave.”
Asked if 30-day distancing practices would be enough or that steps might have to continue longer, she said officials were looking at each area of the country differently as they weigh the data.
“Clearly, there are metro areas that are struggling,” Birx said.
https://www.reuters.com/article/us-health-coronavirus-usa-activity/u-s-planning-ways-to-ease-back-to-normal-if-virus-efforts-work-fauci-idUSKBN21Q1ZM

Roche teams up with Arrakis in RNA-targeted small molecules

Roche (OTCQX:RHHBY +0.7%) has agreed to collaborate with privately held Waltham, MA-based Arrakis Therapeutics to discover RNA-targeted small molecule drugs against a broad range of targets across its (Roche’s) R&D areas.
Arrakis says it has developed a comprehensive drug discovery toolkit that adapts the conventional tools of small molecule drug discovery to address RNA targets instead of proteins while incorporating newly invented tools to establish a broad structure-based drug design platform for RNA.
Under the terms of the deal, Arrakis will lead discovery and research for each target up to a certain point, at which Roche will have the exclusive option to advance the candidate through preclinical and clinical development.
Arrakis will receive $190M in upfront cash, milestones and royalties on net sales, adding that the aggregate value of future payments “exceeds several billion dollars.”
https://seekingalpha.com/news/3559391-roche-teams-up-arrakis-therapeutics-in-rna-targeted-small-molecules

FDA OKs use of Abbott CGM system in hospitals

The FDA has signed off on the use of Abbott’s (ABT -0.0%) FreeStyle Libre 14 day continuous glucose monitoring system in the hospital setting during the COVID-19 pandemic, enabling frontline healthcare workers to remotely monitor inpatient diabetics.
The company is also donating 25K sensors to assist in ramp ups in hard-stricken areas.

PharmaCyte Biotech enters into license agreement for COVID-19 diagnostic kits

PharmaCyte Biotech (OTCQB:PMCB +4.1%) has entered into a license agreement with Hai Kang Life, for sharing certain technology owned or controlled by Hai Kang related to COVID-19 diagnostic kits.
During the term of the Agreement, PharmaCyte is required to pay a monthly fee to Hai Kang in the amount of $6K; this monthly fee increases to $50K once the first Product receives regulatory approval from the U.S. FDA.
In addition, upon the first commercial sale of a Product, PharmaCyte is required to make quarterly royalty payments equal to 10% of Net Sales of any Product sold pursuant to the Agreement.
While Hai Kang is obligated to manufacture any such Product, PharmaCyte cannot assure that the Hai Kang’s manufacture of any Products will comply with U.S. regulatory requirements or that any health care facility or provider will be willing or able to use Products manufactured by Hai Kang.
https://seekingalpha.com/news/3559382-pharmacyte-biotech-enters-license-agreement-for-covidminus-19-diagnostic-kits